摘要
目的分析初始拉米夫定联合阿德福韦酯乙肝肝硬化的疗效,与恩替卡韦单药治疗。方法选取2017年1月至2018年12月张家港市第五人民医院收治的68例乙肝肝硬化患者作为研究对象,分为对照组与试验组,每组34例。对照组用恩替卡韦单药治疗,试验组用初始拉米夫定联合阿德福韦酯治疗。对比两组实验室检查指标变化情况及不良反应发生率。结果治疗后,试验组实验室检查指标优于对照组(P<0.05)。两组均出现胃肠胀气、恶心、头痛等不良反应,经正确处理后可有效缓解,组间对比无统计学意义(P>0.05)。结论初始拉米夫定联合阿德福韦酯治疗乙肝肝硬化效果优于恩替卡韦单药。
Objective Analysis of the efficacy of initial lamivudine combined with adefovir dipivoxil in patients with hepatitis B cirrhosis,and compared with entecavir monotherapy.Methods Sixty-eight patients with hepatitis B cirrhosis admitted to our hospital from January 2011 to December 2018 were divided into control group and test group,with 34 patients in each group.The control group was treated with entecavir monotherapy.The experimental group was treated with initial lamivudine plus adefovir dipivoxil.The changes in laboratory tests and the incidence of adverse reactions were compared.Results After treatment,the laboratory test index of the experimental group was better than that of the control group(P<0.05).Both groups had adverse reactions such as flatulence,nausea,headache,and were effectively relieved after correct treatment.There was no significant difference between the groups(P>0.05).Conclusion The efficacy of initial lamivudine combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis was better than that of entecavir alone.
作者
姚莉
YAO Li(laboratory,Fifth people's Hospital,Zhangjiagang,Jiangsu 215621,China)
出处
《大医生》
2019年第7期145-146,共2页
Doctor
